Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

The World Health Organization today declared the Ebola outbreak in the Democratic Republic of the Congo and Uganda a “public health emergency of international concern” (PHEIC), citing the risk of spread to neighboring countries.

The WHO defines a Public Health Emergency as an extraordinary event or crisis that poses a substantial risk of widespread illness, injury, or death to a population, such as pandemics, severe pollution events, or natural disasters.

However, the WHO clarified that the outbreak, caused by the Bundibugyo virus, does not meet the criteria for a pandemic emergency. Countries sharing land borders with the DRC were described as being at high risk for further spread.

“The Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda constitutes a public health emergency of international concern (PHEIC), but does not meet the criteria of pandemic emergency, as defined in the International Health Regulations (2005) (IHR),” the WHO said in a statement.

Ebola Outbreak: Cases And Deaths

The UN health agency said the outbreak has caused 80 deaths, with eight laboratory-confirmed cases and 246 suspected Ebola cases reported in Ituri Province in the DR Congo, across Bunia, Rwampara, and Mongbwalu.

In addition, two laboratory-confirmed cases — including one death — with no apparent link to each other were reported in Kampala, Uganda, within 24 hours of each other, indicating international spread. Both individuals had travelled separately from the DR Congo.

A laboratory-confirmed case has also been reported in Kinshasa, DR Congo, involving a person returning from Ituri.

The WHO further noted unusual clusters of community deaths and said the outbreak poses a public health risk to other countries through international spread, which has already been documented.

Also read: World Hypertension Day 2026: Why Switching Salt May Be India’s Simplest Weapon Against High Blood Pressure

What Is Bundibugyo Virus Disease?

Bundibugyo virus disease is a rare and deadly illness that has caused outbreaks in several African countries in the past. It is different from other known ebolaviruses such as the Zaire ebolavirus and Sudan ebolavirus.

The virus was first identified during an outbreak in 2007, which resulted in more than 100 cases before being declared over in early 2008.

The WHO described the current outbreak as “extraordinary” because there are no approved Bundibugyo virus-specific therapeutics or vaccines, unlike the Ebola-Zaire strain. Most of the country’s previous outbreaks were caused by the Zaire strain.

How The Virus Spreads

According to US Centers for Disease Control and Prevention (CDC), the Bundibugyo strain spreads through contact with the blood or body fluids of infected individuals or people who have died from the disease.

Transmission can also occur through contact with contaminated objects such as clothing, bedding, needles, and medical equipment, or through infected animals including bats and nonhuman primates.

Symptoms include fever, headache, muscle pain, weakness, diarrhea, vomiting, stomach pain, and unexplained bleeding or bruising in the later stages of illness.

Read More: Can Hantavirus Spread Through Semen And Breast Milk? What Experts Say

WHO Issues Guidelines

The WHO advised immediate isolation of confirmed cases and daily monitoring of contacts. It also recommended restricting national travel for exposed individuals and avoiding international travel until 21 days after exposure.

At the same time, the agency urged countries not to close borders or restrict travel and trade out of fear, warning that such measures could lead to unmonitored informal border crossings.

Health officials at the Africa Centres for Disease Control and Prevention (Africa CDC) today confirmed that the current Ebola outbreak in the Democratic Republic of the Congo and Uganda is being caused by the rare Bundibugyo strain.

Bundibugyo ebolavirus was first isolated during an outbreak of hemorrhagic fever in Uganda in 2007. There are no vaccines or specific treatments approved to prevent or treat the Bundibugyo strain.

Preliminary laboratory results from the Institut National de Recherche Biomedicale (INRB) detected Ebola virus in 13 of 20 samples tested with the Bundibugyo Virus.

"Africa CDC is actively collaborating with health authorities in DRC, Uganda, and regional partners to deliver a coordinated response to confirmed Ebola Virus Disease cases linked to the Bundibugyo strain," the Africa CDC said in a statement.

"Rapid laboratory testing, contact tracing, cross-border surveillance, and enhanced infection prevention measures are already deployed to protect communities and stop the spread," it added.

Ebola Outbreak: Cases And Deaths

As of the latest update from DRC, approximately 246 suspected cases and 65 deaths have been reported, mainly in Mongwalu and Rwampara health zones.

Four deaths have been reported among laboratory-confirmed cases.

Suspected cases have also been reported in Bunia and are pending confirmation. These figures remain provisional and are being validated through laboratory confirmation, line-list harmonization, contact identification, and epidemiological investigation.

Also read: Ebola Resurfaces In Eastern DR Congo In 17th Outbreak, Claims 65 Lives: All You Need To Know

Ebola Bundibugyo Virus Kills Ugandan Man

Uganda’s Ministry of Health, in a statement, reported a confirmed Ebola Bundibugyo Virus Disease case in a 59-year-old Congolese male who was admitted to Kibuli Muslim Hospital on May 11 and died on May 14.

The country's officials reported the case as imported from DRC and have indicated that no local case has yet been confirmed.

Africa CDC noted that it remains concerned by the urban context of Bunia and Rwampara, with intense population movement, insecurity, mining-related mobility in Mongwalu, gaps in contact listing, infection prevention and control challenges, and the proximity of affected areas to Uganda and South Sudan.

What Is Bundibugyo Virus Disease?

Bundibugyo virus disease is a rare and deadly illness that has caused outbreaks in several African countries in the past.

It is also spread by contact with contaminated objects (such as clothing, bedding, needles, and medical equipment), or by contact with animals, such as bats and nonhuman primates, that are infected with BVD.

Symptoms include fever, headache, muscle pain, weakness, diarrhea, vomiting, stomach pain, and unexplained bleeding or bruising (a late stage of illness).

Read More: National Dengue Day 2026: India Reports 6,927 Cases And 10 Deaths In 2026

Ebola Outbreak: Here's How To Prevent

The US CDC advised people to avoid:

• contact with people who have symptoms such as fever, muscle pain, and rash
• contact with blood and other body fluids or objects that are contaminated with them
• visiting healthcare facilities in the affected areas for nonurgent medical care or for non-medical reasons. Avoid visiting traditional healers in the affected areas
• contact with dead bodies or items that have been in contact with dead bodies
• participating in funeral or burial practices that involve touching the body of someone who has died
• contact with bats, forest antelopes, nonhuman primates (e.g., monkeys, chimpanzees, gorillas), and blood, fluids, or raw meat from these or unknown animals.
• going into areas where bats live, such as mines or caves.

In case of infection, the CDC advises:

• Monitoring for symptoms of BVD while in the outbreak area and for 21 days after leaving.
• If you develop fever, headache, muscle pain, weakness, diarrhea, vomiting, stomach pain, and unexplained bleeding or bruising (a late stage of illness)
• Isolate immediately
• Do not travel.
• Contact local health authorities

Even as the world is still grappling with the news of a hantavirus and two separate norovirus outbreaks, the Africa Centres for Disease Control and Prevention (Africa CDC) today confirmed that the Ebola virus has resurfaced in eastern Democratic Republic of the Congo for the 17th time.

In a statement, the Africa CDC reported that there are 246 suspected cases and 65 deaths, mainly in the mining areas of Mongwalu and Rwampara, about 100 kilometers north of the provincial capital, Bunia.

While tests are being carried out to identify the strain of the virus, early indications suggest the strain is not the Zaire variant, which has been responsible for several previous outbreaks in the country, the health officials said.

The Ebola Zaire strain was prominent in Congo’s past outbreaks, including the 2018 to 2020 outbreak in the eastern region that killed more than 1,000 people.

Ebola: 17th outbreak in DR Congo

Ebola was first discovered in 1976 in the DR Congo. This is the 17th outbreak of the deadly viral disease in the country.

As per preliminary tests conducted at the Institut National de Recherche Biomédicale (INRB) in the country's capital, Kinshasa, the Ebola virus has been detected in 13 of 20 samples analysed, following consultations with DR Congo's Ministry of Health and National Public Institute.

Of the 65 deaths, four were reported among lab-confirmed cases, Africa CDC said.

Additional suspected cases have also been reported in Ituri's provincial capital, Bunia, a densely populated urban centre near the borders with Uganda and South Sudan, raising fears of regional transmission.

All affected communities and at-risk areas have been advised to follow guidelines from the national health authorities.

Also read: More Americans Exposed To Hantavirus; 41 Under Monitoring, Says CDC

What Is Ebola Virus Disease?

As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal.

People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person, such as saliva, urine, feces, or semen, or things that have body fluids of an infected person, like clothes or sheets.

How Does Transmission Work?

Read More: Another Norovirus Outbreak Confirmed Aboard Cruise Ship In France; Over 1,700 People Trapped

Ebola enters the body through cuts in the skin or when one touches their eyes, nose, or mouth. Early symptoms include fever, fatigue, and headache.

It is a highly infectious and transmissible disease; in fact, there have been cases of healthcare workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.

Cases of people conducting burial ceremonies, involving direct contact with the body of the deceased, can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk or in pregnancy-related fluids and tissues.

Symptoms include:

• feeling tired
• headache
• muscle and joint pain
• eye pain and vision problems
• weight gain
• belly pain and loss of appetite
• hair loss and skin problems
• trouble sleeping
• memory loss
• hearing loss
• depression and anxiety.

Is There Any Vaccine for Ebola?

According to the WHO, there are two vaccines against the Ebola virus. But both the Merck-developed Ervebo vaccine, administered in one dose, and Johnson & Johnson-developed Zabdeno and Mvabea vaccine, administered in a two-dose regimen, target Zaire ebolavirus.

The Ervebo vaccine is recommended for use in outbreak settings and is currently the only vaccine available in the global stockpile.